Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals
- 228 Downloads
Recently, two conflicting articles about recurrence of hepatocellular carcinoma (HCC) after direct acting antivirals (DAA) against hepatitis C virus (HCV) were published. We investigated the relationship between DAA and HCC recurrence. Eligible patients were (1) history of HCC and treated curatively with interventions, and (2) interferon-free DAA therapy was initiated after eradication of HCC. We analyzed contributing factor for HCC recurrence. Ten out of 23 participants (43%) encountered recurrence of HCC. Age, sex, diabetes mellitus, fibrosis score, chemistry, and alpha-fetoprotein did not differ between patients with recurrence and patients without recurrence. The patients with recurrence had significantly higher values of antibody to hepatitis B core antigen (anti-HBc) than the patients without recurrence, 6.06±3.75 vs. 0.91±2.43 (p=0.0019). The relative risk of HCC recurrence comparing anti-HBc positive to negative was 5.2 (95% confidence interval 1.40 to 19.32). Odds ratio was 22.0 (95% confidence interval 2.5 to 191.1). We conclude that anti-HBc positivity was a strong contributing factor for HCC recurrence after DAA therapy.
KeywordsDirect acting antivirals HBc antibody Hepatitis B virus Hepatocellular carcinoma Recurrence Recurrence of HCC
This study was supported, in part, by the Research Program on Hepatitis research from the Japan Agency for Medical Research and Development, AMED, and a grant for Practical Research on Hepatitis B from the Ministry of Health, Labour, and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Compliance with ethical standards
Conflict of interest
HS, KM, SI, TF, MN, KT, HT, HN, MN, and TW declare that they have no conflict of interest.
Not required, because this was a retrospective analysis of the past clinical records.
- 2.Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–40.Google Scholar
- 3.Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008;43:849–56.CrossRefPubMedGoogle Scholar